This content is machine translated Acute lymphoblastic leukemia Bispecific antibody in heavily pretreated patients. Blinatumomab forms a bridge between T cells and cancer cells. The bispecific antibody is proving its worth in a new phase III trial. It has been approved in Switzerland for…
View Post 6 min This content is machine translated Highlights from the ECTRIMS Congress 2013 New therapeutic approaches and an exciting hypothesis on the pathogenesis From October 2-5, 2013, the 29th ECTRIMS (Congress of the European Committee for Research and Treatment in Multiple Sclerosis) and the 18th RIMS (Annual Conference of Rehabilitation in MS) were…
View Post 3 min This content is machine translated Approval Teriflunomide (Aubagio®) Significantly lower risk of disability progression The more a patient with MS is limited in different areas of life by his increasing disability, the worse his health status becomes. In Switzerland, an oral MS treatment, teriflunomide,…
